Cargando…

Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease‐related declines

INTRODUCTION: Objectively‐defined subtle cognitive decline (Obj‐SCD) and plasma phosphorylated‐tau181 (p‐tau181) are promising early Alzheimer's disease (AD) markers. However, associations between Obj‐SCD and p‐tau181, and their combined prognostic potential, are unknown. METHODS: Baseline and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thomas, Kelsey R., Bangen, Katherine J., Edmonds, Emily C., Weigand, Alexandra J., Walker, Kayla S., Bondi, Mark W., Galasko, Douglas R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Blood‐based Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515224/ https://www.ncbi.nlm.nih.gov/pubmed/34692978 http://dx.doi.org/10.1002/dad2.12238

Ejemplares similares

Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint
por: Thomas, Kelsey R., et al.
Publicado: (2022)

Reduced plasma desmosterol-to-cholesterol ratio and longitudinal cognitive decline in Alzheimer's disease
por: Sato, Yoshiaki, et al.
Publicado: (2015)

Amyloid-β sequester proteins as blood-based biomarkers of cognitive decline
por: Uchida, Kazuhiko, et al.
Publicado: (2015)

Elevated plasma neurofilament light in aging reflects brain white‐matter alterations but does not predict cognitive decline or Alzheimer's disease
por: Nyberg, Lars, et al.
Publicado: (2020)

Cognitive Heterogeneity and Risk of Progression in Data-Driven Subtle Cognitive Decline Phenotypes
por: Thomas, Kelsey R., et al.
Publicado: (2022)

Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease
por: Raket, Lars Lau, et al.
Publicado: (2020)

Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia
por: Shen, Xue‐Ning, et al.
Publicado: (2020)

Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort
por: Gonzales, Mitzi M., et al.
Publicado: (2022)

Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
por: Triana‐Baltzer, Gallen, et al.
Publicado: (2021)

Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile
por: Winston, Charisse N., et al.
Publicado: (2016)

MicroRNA deregulation and chemotaxis and phagocytosis impairment in Alzheimer's disease
por: Guedes, Joana R., et al.
Publicado: (2015)

A blood screening test for Alzheimer's disease
por: O'Bryant, Sid E., et al.
Publicado: (2016)

Plasma clusterin levels and risk of dementia, Alzheimer's disease, and stroke
por: Weinstein, Galit, et al.
Publicado: (2016)

Apolipoproteins and Alzheimer's pathophysiology
por: Koch, Manja, et al.
Publicado: (2018)

Molecular markers of neuropsychological functioning and Alzheimer's disease
por: Edwards, Melissa, et al.
Publicado: (2015)

Blood-based metabolic signatures in Alzheimer's disease
por: de Leeuw, Francisca A., et al.
Publicado: (2017)

The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis
por: Forgrave, Lauren M., et al.
Publicado: (2019)

Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia
por: van Wijk, Nick, et al.
Publicado: (2017)

Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging
por: Gupta, Veer Bala, et al.
Publicado: (2015)

Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease
por: Doody, Rachelle S., et al.
Publicado: (2015)

Deep learning shows no morphological abnormalities in neutrophils in Alzheimer's disease
por: Chabrun, Floris, et al.
Publicado: (2021)

Plasma microRNA vary in association with the progression of Alzheimer's disease
por: Guévremont, Diane, et al.
Publicado: (2022)

Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology
por: Savica, Rodolfo, et al.
Publicado: (2016)

Crosswalk study on blood collection‐tube types for Alzheimer's disease biomarkers
por: Jonaitis, Erin M., et al.
Publicado: (2022)

Alterations of membrane protein expression in red blood cells of Alzheimer's disease patients
por: Várady, György, et al.
Publicado: (2015)

The global Alzheimer's Association round robin study on plasma amyloid β methods
por: Pannee, Josef, et al.
Publicado: (2021)

Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles
por: Keshavan, Ashvini, et al.
Publicado: (2018)

Effects of pre‐analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges
por: O'Bryant, Sid E., et al.
Publicado: (2015)

Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers
por: DeMarshall, Cassandra A., et al.
Publicado: (2016)

Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis
por: Janssens, Jana, et al.
Publicado: (2018)

MCP-1 and eotaxin-1 selectively and negatively associate with memory in MCI and Alzheimer's disease dementia phenotypes
por: Bettcher, Brianne M., et al.
Publicado: (2016)

The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment
por: Klavins, Kristaps, et al.
Publicado: (2015)

LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project
por: de Leeuw, Francisca A., et al.
Publicado: (2020)

Aβ misfolding in blood plasma measured by immuno‐infrared‐sensor as an age‐independent risk marker of Alzheimer's disease
por: Möllers, Tobias, et al.
Publicado: (2021)

Blood‐based biomarkers for Alzheimer's pathology and the diagnostic process for a disease‐modifying treatment: Projecting the impact on the cost and wait times
por: Mattke, Soeren, et al.
Publicado: (2020)

Association between serum urate and CSF markers of Alzheimer's disease pathology in a population‐based sample of 70‐year‐olds
por: Fatima, Tahzeeb, et al.
Publicado: (2021)

Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease
por: Peloso, Gina M., et al.
Publicado: (2018)

A novel detection method of cleaved plasma high-molecular-weight kininogen reveals its correlation with Alzheimer's pathology and cognitive impairment
por: Yamamoto-Imoto, Hitomi, et al.
Publicado: (2018)

Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort
por: Gupta, Veer Bala, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7gfvlu53edu7n9fe2stqbilq65